Pamela Esposito's most recent trade in Kymera Therapeutics Inc was a trade of 4,900 Common Stock done at an average price of $68.0 . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 67.99 per share. | 20 Jan 2026 | 4,900 | 200 | - | 68.0 | 333,145 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 3,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.20 per share. | 20 Jan 2026 | 3,000 | 3,000 | - | 31.2 | 93,600 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 2,500 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 49.10 per share. | 20 Jan 2026 | 2,500 | 5,500 | - | 49.1 | 122,750 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 66.68 per share. | 20 Jan 2026 | 400 | 5,100 | - | 66.7 | 26,672 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 68.52 per share. | 20 Jan 2026 | 200 | 0 | - | 68.5 | 13,704 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 81.56 per share. | 17 Dec 2025 | 14,505 | 13,058 | - | 81.6 | 1,182,984 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 49.10 per share. | 17 Dec 2025 | 12,563 | 12,563 | - | 49.1 | 616,843 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 12,563 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.67 per share. | 17 Dec 2025 | 12,000 | 24,563 | - | 27.7 | 332,040 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 82.34 per share. | 17 Dec 2025 | 7,959 | 5,099 | - | 82.3 | 655,362 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 83.45 per share. | 17 Dec 2025 | 4,099 | 1,000 | - | 83.5 | 342,064 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 3,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.20 per share. | 17 Dec 2025 | 3,000 | 27,563 | - | 31.2 | 93,600 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 84.07 per share. | 17 Dec 2025 | 1,000 | 0 | - | 84.1 | 84,070 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 5,000 | 24,127 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.55 per share. | 03 Jun 2025 | 5,000 | 5,000 | - | 29.6 | 147,750 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 49.04 per share. | 03 Jun 2025 | 5,000 | 0 | - | 49.0 | 245,186 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 02 Dec 2024 | 2,500 | 0 | - | 49 | 122,500 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 2,500 | 29,127 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.55 per share. | 02 Dec 2024 | 2,500 | 2,500 | - | 29.6 | 73,875 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 8,500 | 31,627 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.55 per share. | 17 Sep 2024 | 8,500 | 8,500 | - | 29.6 | 251,175 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 48.75 per share. | 17 Sep 2024 | 7,150 | 0 | - | 48.8 | 348,581 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 47.75 per share. | 17 Sep 2024 | 6,350 | 7,150 | - | 47.7 | 303,185 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 5,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 17 Sep 2024 | 5,000 | 13,500 | - | 14.2 | 70,900 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 22 Aug 2023 | 18,600 | 263,436 (0%) | 0% | 20.0 | 372,186 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 22 Aug 2023 | 13,600 | 277,036 (0%) | 0% | 3.3 | 44,880 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 13,600 | 91,691 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 5,000 | 35,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 22 Aug 2023 | 5,000 | 282,036 (0%) | 0% | 15.5 | 77,500 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 11 Aug 2023 | 1,400 | 263,436 (0%) | 0% | 20 | 28,000 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 1,400 | 105,291 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 11 Aug 2023 | 1,400 | 264,836 (0%) | 0% | 3.3 | 4,620 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.63 per share. | 10 Jul 2023 | 17,923 | 265,513 (0%) | 0% | 21.6 | 387,674 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 15,000 | 106,691 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 10 Jul 2023 | 15,000 | 278,436 (0%) | 0% | 3.3 | 49,500 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 10 Jul 2023 | 5,000 | 283,436 (0%) | 0% | 15.5 | 77,500 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 5,000 | 40,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 10 Jul 2023 | 2,077 | 263,436 (0%) | 0% | 21.1 | 43,866 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 5,966 | 263,436 (0%) | 0% | 18.0 | 107,686 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 40,000 | 269,402 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 09 Dec 2022 | 15,000 | 229,402 (0%) | 0% | 25.0 | 375,450 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 09 Dec 2022 | 15,000 | 244,402 (0%) | 0% | 1.0 | 15,150 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 15,000 | 36,203 | - | - | Employee Stock Option (right to buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 3,507 | 229,402 (0%) | 0% | 14.6 | 51,167 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 34,125 | 34,125 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 22,750 | 232,909 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2021 | 12,538 | 51,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.17 per share. | 20 Jul 2021 | 12,538 | 210,159 (0%) | 0% | 33.2 | 415,885 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 20 Jul 2021 | 12,538 | 222,697 (0%) | 0% | 1.0 | 12,663 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 20 Jul 2021 | 4,862 | 215,021 (0%) | 0% | 1.0 | 4,911 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.05 per share. | 20 Jul 2021 | 4,862 | 210,159 (0%) | 0% | 33.0 | 160,689 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2021 | 4,862 | 63,741 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 15 Jul 2021 | 4,600 | 214,759 (0%) | 0% | 1.0 | 4,646 | Common Stock |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 4,600 | 68,603 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.37 per share. | 15 Jul 2021 | 4,600 | 210,159 (0%) | 0% | 33.4 | 153,502 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,063 | 20,063 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 51,250 | 51,250 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 34,165 | 210,159 (0%) | 0% | 0 | Common Stock |